Insulin and lysophosphatidylcholine synergistically stimulate NO-dependent cGMP production in human endothelial cells

Diabetic Medicine

Volumn 20, Issue 10, 2003, Pages 838-845

  Konopatskaya, O ^a   Whatmore, J L ^a   Tooke, J E ^a   Shore, A C ^a  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

Author keywords

eNOS; Insulin; Lyso PC; Nitric oxide; Translocation

Indexed keywords

CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INSULIN; LYSOPHOSPHATIDYLCHOLINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NITRIC OXIDE SYNTHASE; NOS3 PROTEIN, HUMAN;

ARTICLE; CELL CULTURE; CELL FRACTIONATION; CYTOSOL; DESENSITIZATION; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MEMBRANE TRANSPORT; PROTEIN EXPRESSION; STIMULATION; WESTERN BLOTTING; BIOSYNTHESIS; CELL MEMBRANE; DRUG POTENTIATION; ENZYMOLOGY; IMMUNOBLOTTING; METABOLISM; METHODOLOGY; NONPARAMETRIC TEST; TRANSPORT AT THE CELLULAR LEVEL; VASCULAR ENDOTHELIUM;

BIOLOGICAL TRANSPORT; CELL MEMBRANE; CYCLIC GMP; CYTOSOL; DRUG SYNERGISM; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOBLOTTING; INSULIN; LYSOPHOSPHATIDYLCHOLINES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; STATISTICS, NONPARAMETRIC; STIMULATION, CHEMICAL;

EID: 0642312200     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2003.01039.x     Document Type: Article

References (56)

1. Ignarro LJ. Nitric oxide: a unique endogenous signaling molecule in vascular biology. Biosc Rep 1999; 19: 51-71.
2. Honing ML, Morrison PJ, Banga JD, Stroes ES, Rabelink TJ. Nitric oxide availability in diabetes mellitus. Diabetes Metab Rev 1998; 14: 241-249.
3. Napoli C, Ignarro L. Nitric oxide and atherosclerosis. Nitric Oxide 2001; 5: 88-97.
4. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-142.
5. Sessa WC, Garcia-Cardena G, Liu J, Keh A, Pollock JS, Bradley J et al. The Golgi association of endothelial nitric oxide synthase is necessary for the efficient synthesis of nitric oxide. J Biol Chem 1995; 270: 17641-17644.
6. Liu J, Hughes TE, Sessa WC. The first 35 amino acids and fatty acylation sites determine the molecular targeting of endothelial nitric oxide synthase into the Golgi region of cells: a green fluorescent protein study. J Cell Biol 1997; 137: 1525-1535.
7. Sowa G, Liu J, Papapetropoulos A, Rex-Haffner M, Hughes TE, Sessa WC. Trafficking of endothelial nitric-oxide synthase in living cells. Quantitative evidence supporting the role of palmitoylation as a kinetic trapping mechanism limiting membrane diffusion. J Biol Chem 1999; 274: 22524-22531.
8. Garcia-Cardena G, Oh P, Liu J, Schnitzer JE, Sessa WC. Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling. Proc Natl Acad Sci USA 1996; 93: 6448-6453.
9. Shaul PW, Smart EJ, Robinson LJ, German Z, Yuhanna IS, Ying Y et al. Acylation targets endothelial nitric-oxide synthase to plasmalemmal caveolae. J Biol Chem 1996; 271: 6518-6522.
10. Liu J, Garcia-Cardena G, Sessa WC. Palmitoylation of endothelial nitric oxide synthase is necessary for optimal stimulated release of nitric oxide: implications for caveolae localization. Biochemistry 1996; 35: 13277-13281.
11. Garcia-Cardena G, Martasek P, Masters BS, Skidd PM, Couet J, Li S et al. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the NOS caveolin binding domain in vivo. J Biol Chem 1997; 272: 25437-25440.
12. Feron O, Saldana F, Michel JB, Michel T. The endothelial nitric-oxide synthase-caveolin regulatory cycle. J Biol Chem 1998;273:3125-3128.
13. Prabhakar P, Thatte HS, Goerz RM, Cho MR, Golan DE, Michel T. Receptor-regulated translocation of endothelial nitric-oxide synthase. J Biol Chem 1998; 273: 27383-27388.
14. Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995; 270: 319-324.
15. Dart AM, Chin-Dusting JP. Lipids and the endothelium. Cardiovasc Res 1999; 43: 308-322.
16. Steinbreche UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 1984; 81: 3883-3887.
17. Parthasarathy S, Steinbrecher UP, Barnert J, Witztum JL, Steinberg D. Essential role of phospholipase A2 activity in endothelial cell-induced modification of low density lipoprotein. Proc Natl Acad Sci USA 1985; 82: 3000-3004.
18. Liu SY, Lu X, Choy S, Dembinski TC, Hatch GM, Mymin D et al. Alteration of lysophosphatidylcholine content in low density lipoprotein after oxidative modification: relationship to endothelium dependent relaxation. Cardiovasc Res 1994; 28: 1476-1481.
19. Portman OW, Alexander M. Lysophosphatidylcholine concentrations and metabolism in aortic intima plus inner media: effect of nutritionally induced atherosclerosis. J Lipid Res 1969; 10: 158-165.
20. Kinnaird AA, Choy PC, Man RY. Lysophosphatidylcholine accumulation in the ischemic canine heart. Lipids 1988; 23: 32-35.
21. Harada N, Kashiwagi A, Nishio Y, Kikkawa R. Effects of cholesterol-lowering treatments on oxidative modification of plasma intermediate density lipoprotein plus low density lipoprotein fraction in Type 2 diabetic patients. Diabetes Res Clin Pract 1999; 43: 111-120.
22. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA 1988; 85: 2805-2809.
23. McMurray HF, Parthasarathy S, Steinberg D. Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes. J Clin Invest 1993; 92: 1004-1008.
24. Sakai M, Miyazaki A, Hakamata H, Sasaki T, Yui S, Yamazaki M et al. Lysophosphatidylcholine plays an essential role in the mitogenic effect of oxidized low density lipoprotein on murine macrophages. J Biol Chem 1994; 269: 31430-31435.
25. Saito T, Wolf A, Menon NK, Saeed M, Alves C, Bing RJ. Lysolecithins as endothelium-dependent vascular smooth muscle relaxants that differ from endothelium-derived relaxing factor (nitric oxide). Proc Natl Acad Sci USA 1988; 85: 8246-8250.
26. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990; 344: 160-162.
27. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 1994; 94: 1172-1179.
28. Sobrevia L, Nadal A, Yudilevich DL, Mann GE. Activation of 1-arginine transport (system y+) and nitric oxide synthase by elevated glucose and insulin in human endothelial cells. J Physiol 1996; 490: 775-781.
29. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 1996; 98: 894-898.
30. Jaffe EA, Nachman RL, Becker CG, Minick C. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745-2756.
31. Murad F. Cyclic guanosine monophosphate as a mediator of vasodilation. J Clin Invest 1986; 78: 1-5.
32. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
33. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
34. Furchgott R. Role of endothelium in responses of vascular smooth muscle. Circ Res 1983; 53: 557-573.
35. Baron AD. Hemodynamic actions of insulin. Am J Physiol 1994; 267: E187-E202.
36. Kinoshita J, Tanaka Y, Niwa M, Yoshii H, Takagi M, Kawamori R. Impairment of insulin-induced vasodilation is associated with muscle insulin resistance in type 2 diabetes. Diabetes Res Clin Pract 2000; 47: 185-190.
37. Bar R, Boes M, Dake BL, Booth BA, Henley SA, Sandra A. Insulin, insulin-like growth factors, and vascular endothelium. Am J Med 1988; 28: 59-70.
38. Darby SM, Miller ML, Allen RO, LeBeau M. A mass spectrometric method for quantitation of intact insulin in blood samples. J Anal Toxicol 2001; 25: 8-14.
39. 2+ but requires phosphorylation by Akt and Ser (1179). J Biol Chem 2001; 276: 30392-30398.
40. Yokoyama M, Hirata K, Miyake R, Akita H, Ishikawa Y, Fukuzaki H. Lysophosphatidylcholine: essential role in the inhibition of endothelium-dependent vasorelaxation by oxidized low density lipoprotein. Biochem Biophys Res Commun 1990; 168: 301-308.
41. Hirata K, Miki N, Kuroda Y, Sakoda T, Kawashima S, Yokoyama M. Low concentration of oxidized low-density lipoprotein and lysophosphatidylcholine upregulate constitutive nitric oxide synthase mRNA expression in bovine aortic endothelial cells. Circ Res 1995; 76: 958-962.
42. Zembowicz A, Tang JL, Wu KK. Transcriptional induction of endothelial nitric oxide synthase type III by lysophosphatidylcholine. J Biol Chem 1995; 270: 17006-17010.
43. Bergmann SR, Ferguson TB Jr, Sobel BE. Effects of amphiphiles on erythrocytes, coronary arteries, and perfused hearts. Am J Physiol 1981; 240: H229-H237.
44. Stoll LL, Oskarsson HJ, Spector AA. Interaction of lysophosphatidylcholine with aortic endothelial cells. Am J Physiol 1992; 262: H1853-H1860.
45. Parton RG. Caveolae and caveolins. Curr Opin Cell Biol 1996; 8: 542-548.
46. Shaul PW, Anderson RG. Role of plasmalemmal caveolae in signal transduction. Am J Physiol 1998; 275: L843-L851.
47. Yamamoto M, Toya Y, Schwencke C, Lisanti MP, Myers MG Jr, Ishikawa Y. Caveolin is an activator of insulin receptor signaling. J Biol Chem 1998; 273: 26962-26968.
48. Gustavsson J, Parpal S, Karlsson M, Ramsing C, Thorn H, Borg M et al. Localization of the insulin receptor in caveolae of adipocyte plasma membrane. FASEB J 1999; 13: 1961-1971.
49. Yamashita T, Kawashima S, Ohashi Y, Ozaki M, Rikitake Y, Inoue N et al. Mechanisms of reduced nitric oxide/cGMP-mediated vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. Hypertension 2000; 36: 97-102.
50. Scott WS, Nakayama DK. Sustained nitric oxide exposure decreases soluble guanylate cyclase mRNA and enzyme activity in pulmonary artery smooth muscle. J Surg Res 1998; 79: 66-70.
51. Meininger CJ, Marinos RS, Hatakeyama K, Martinez-Zaguilan R, Rojas JD, Kelly KA et al. Impaired nitric oxide production in coronary endothelial cells of the spontaneously diabetic BB rat is due to tetrahydrobiopterin deficiency. Biochem J 2000; 349: 353-356.
52. Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, Karoui H et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA 1998; 95: 9220-9225.
53. Goligorsky MS, Li H, Brodsky S, Chen J. Relationships between caveolae and eNOS: everything in proximity and the proximity of everything. Am J Physiol Renal Physiol 2002; 283: F1-F10.
54. Brausewetter F, Jehle PM, Jung MF, Boehm BO, Brueckel J, Hombach V et al. Microvascular permeability is increased in both types of diabetes and correlates differentially with serum levels of insulin-like growth factor I (IGF-I) and vascular endothelial growth factor (VEGF). Horm Metab Res 2001; 33: 713-720.
55. Aiello LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int Suppl 2000; 77: S113-S119.
56. Kroncke K-D, Suschek CV, Kolb-Bachofen V. Implications of inducible nitric oxide synthase expression and enzyme activity. Aniox Redox Signal 2000; 2: 585-605.